{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:51:21Z","timestamp":1790650281955,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007930","name":"Institute of Clinical and Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.vaccine.2020.11.051","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T20:28:45Z","timestamp":1611260925000},"page":"1339-1348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65\u00a0years and older"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4826-1790","authenticated-orcid":false,"given":"Patricia","family":"Winokur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-4420","authenticated-orcid":false,"given":"Evan J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-5536","authenticated-orcid":false,"given":"Wilbur H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.051_b0005","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2020.11.051_b0010","unstructured":"WHO. Avian and other zoonotic influenza. 2018."},{"key":"10.1016\/j.vaccine.2020.11.051_b0015","unstructured":"Centers for Disease Control and Prevention. 2016, November 3."},{"key":"10.1016\/j.vaccine.2020.11.051_b0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.1124513","article-title":"Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus","volume":"312","author":"Stevens","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.11.051_b0025","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1128\/JVI.03173-15","article-title":"Two Outbreak Sources of Influenza A (H7N9) Viruses Have Been Established in China","volume":"90","author":"Wang","year":"2016","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0030","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.15585\/mmwr.mm6549a2","article-title":"Assessing Change in Avian Influenza A(H7N9) Virus Infections During the Fourth Epidemic - China, September 2015-August 2016","volume":"65","author":"Xiang","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2020.11.051_b0035","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1126\/science.1240532","article-title":"H7N9 influenza viruses are transmissible in ferrets by respiratory droplet","volume":"341","author":"Zhang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.11.051_b0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.1239844","article-title":"Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs","volume":"341","author":"Zhu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.11.051_b0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.11.051_b0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2017.07.021","article-title":"Epidemiological and clinical characteristics of humans with avian influenza A (H7N9) infection in Guangdong, China, 2013\u20132017","volume":"65","author":"Yang","year":"2017","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0055","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1016\/j.vaccine.2007.08.042","article-title":"Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects","volume":"25","author":"Couch","year":"2007","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.166.10.1121","article-title":"Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons","volume":"166","author":"Keitel","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.vaccine.2020.11.051_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0264-410X(93)90333-S","article-title":"Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers","volume":"11","author":"Palache","year":"1993","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01320555","article-title":"Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine","volume":"47","author":"Ruben","year":"1975","journal-title":"Arch Virol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0075","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/S0264-410X(03)00456-0","article-title":"Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults","volume":"21","author":"Frey","year":"2003","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0080","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/526537","article-title":"Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans","volume":"197","author":"Zangwill","year":"2008","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respir Viruses."},{"key":"10.1016\/j.vaccine.2020.11.051_b0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0100","first-page":"1043","article-title":"A Goodness-of-Fit Tests for the Multiple Logistic Regression Model. Communications","author":"Hosmer","year":"1980","journal-title":"Statistics."},{"key":"10.1016\/j.vaccine.2020.11.051_b0105","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","author":"Bart","year":"2014623455","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.vaccine.2020.11.051_b0110","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant viruslike particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2020.11.051_b0115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.11.051_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(15)00378-3","article-title":"H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Rudenko","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0125","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.vaccine.2017.06.044","article-title":"Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I\/II, prospective, randomized, open-label trial","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5f2ae0fb-53f1-48c2-aa19-9114765ba029","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.051_b0135","first-page":"136","article-title":"A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A\/H5N1 influenza vaccine in adult and elderly subjects","volume":"53","author":"Czajka","year":"2012","journal-title":"J Prev Med Hyg."},{"key":"10.1016\/j.vaccine.2020.11.051_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0264-410X(98)00185-6","article-title":"Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons","volume":"17","author":"Minutello","year":"1999","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0145","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59((R))-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2020.11.051_b0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1086\/599992","article-title":"Safety and immunogenicity of multiple and higher doses of an inactivated influenza A\/H5N1 vaccine","volume":"200","author":"Beigel","year":"2009","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0155","article-title":"Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials","volume":"8","author":"Domnich","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.11.051_b0160","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/irv.12445","article-title":"Workshop report: Immunoassay standardisation for \u201cuniversal\u201d influenza vaccines","volume":"11","author":"Pavlova","year":"2017","journal-title":"Influenza Other Respir Viruses."},{"key":"10.1016\/j.vaccine.2020.11.051_b0165","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.vaccine.2019.06.039","article-title":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines","volume":"37","author":"Hauser","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0170","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02259-16","article-title":"Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses","volume":"91","author":"Kwon","year":"2017","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0180","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2020.11.051_b0185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0190","series-title":"Arnaud Didierlaurent","author":"Giuseppe Del Giudice","year":"2018"},{"key":"10.1016\/j.vaccine.2020.11.051_b0195","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0200","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.051_b0205","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/cid\/cit060","article-title":"Influenza vaccine effectiveness in the community and the household","volume":"56","author":"Ohmit","year":"2013","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiv087","article-title":"Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine","volume":"212","author":"Winokur","year":"2015","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0215","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2020.11.051_b0220","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/258430","article-title":"Possible Triggering Effect of Influenza Vaccination on Psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J Immunol Res."},{"key":"10.1016\/j.vaccine.2020.11.051_b0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000362808","article-title":"National survey of psoriasis flares after 2009 monovalent H1N1\/seasonal vaccines","volume":"229","author":"Sbidian","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.vaccine.2020.11.051_b0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5021\/ad.2013.25.4.489","article-title":"New Onset Guttate Psoriasis Following Pandemic H1N1 Influenza Vaccination","volume":"25","author":"Shin","year":"2013","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.vaccine.2020.11.051_b0235","first-page":"68","article-title":"Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population","volume":"3","author":"Reber","year":"2012","journal-title":"Aging Dis."},{"key":"10.1016\/j.vaccine.2020.11.051_b0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","article-title":"Fluad(R)-MF59(R)-Adjuvanted Influenza Vaccine in Older Adults","volume":"45","author":"Tsai","year":"2013","journal-title":"Infect Chemother."},{"key":"10.1016\/j.vaccine.2020.11.051_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph14030263","article-title":"Comparative Epidemiology of Human Fatal Infections with Novel, High (H5N6 and H5N1) and Low (H7N9 and H9N2) Pathogenicity Avian Influenza A Viruses","volume":"14","author":"Wu","year":"2017","journal-title":"Int J Environ Res Public Health."},{"key":"10.1016\/j.vaccine.2020.11.051_b0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.11.051_b0255","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1073\/pnas.0601266103","article-title":"Mitigation strategies for pandemic influenza in the United States","volume":"103","author":"Germann","year":"2006","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:39Z","timestamp":1759402419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0264410X20315048"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65\u00a0years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}